Medical/Pharmaceuticals
Terumo Establishes Group-wide 'DE&I Philosophy' to Further Cultivate a Diverse, Equitable and Inclusive Culture
TOKYO, Mar. 1, 2022 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced that it has established a global "DE&I Philosophy" to further cultivate the culture of Diversity, Equity, and Inclusion (DE&I) at the Terumo Group. Additionally, a "DE&I Guiding Principle" has also been defined to ...
2022-03-01 09:00
2916
Bangkok Dusit Medical Services embarks on sponsorship campaign with CNN focused on global health issues and healthy living
HONG KONG, March 1, 2022 /PRNewswire/ -- Bangkok Dusit Medical Services Public
Company Limited (BDMS), the largest healthcare network inThailand, is extending
its long-standing partnership with CNN International Commercial (CNNIC) with
the sponsorship of 'Vital Signs
2022-03-01 09:00
4400
Innovent Biologics and AnHeart Therapeutics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, March 1, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2022-03-01 08:48
4310
Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2022
Added 18,985 New Subscribers in 3Q22 Revenues Up 9.1% YoY to RMB317.2 Million ($49.8 Million) Gross Profit Up 9.8% YoY to RMB269.9 Million ($42.4 Million) Operating Income Up 20.8% YoY to RMB149.7 Million ($23.5 Million) Non-GAAP Operating Income Up 18.6% YoY to RMB161.6 Million ($25.4 Mil...
2022-03-01 05:16
4332
Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial
- NVX-CoV2373 demonstrates protection against symptomatic and asymptomatic infection - High level of vaccine efficacy maintained over a 6-month period of surveillance - Continued reassuring safety profile in line with previous trials GAITHERSBURG, Md., March 1, 2022 /PRNewswire/ -- Novavax, In...
2022-03-01 05:01
4430
MIM Software Inc. Announces Global Partnership with GenesisCare
CLEVELAND, Feb. 28, 2022 /PRNewswire/ -- MIM Software Inc. announced today a partnership with leading global provider of integrated cancer care, GenesisCare, to increase patient access to world-class care on a global scale. GenesisCare's clinical teams treat more than 400,000 patients at more tha...
2022-02-28 23:15
2236
Biocon Biologics to Acquire Viatris' Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
BENGALURU, India, Feb. 28, 2022 /PRNewswire/ -- Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523) (NSE: BIOCON), has entered into a definitive agreement with its partner Viatris Inc. (NASDAQ: VTRS). Accordingly, Biocon Biologics Ltd. (BBL) will acquire Viatris' biosimilars bus...
2022-02-28 22:15
4740
Inspira Technologies Applauded by Frost & Sullivan for Minimizing the Need for Invasive Mechanical Ventilation with Its Innovative Technology, the ART™ System
Inspira Technologies aims to set a new standard of care in the respiratory care industry by introducing its ART system. SAN ANTONIO, Feb. 28, 2022 /PRNewswire/ -- Frost & Sullivan recently analyzed the European artificial respiratory market and, based on its findings, recognizesInspira Technolog...
2022-02-28 22:00
2075
PHASE II CLINICAL STUDY AT WEILL CORNELL MEDICAL CENTER INVESTIGATING PAXALISIB IN COMBINATION WITH METFORMIN AND A KETOGENIC DIET ENROLLS FIRST PATIENT
SYDNEY, Feb. 28, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investigational new drug, paxalisib, in combination with metformin and a ketogenic diet for the treatmen...
2022-02-28 21:00
3429
Argon Medical Devices Celebrates Its 50th Anniversary
Industry leader highlights its longevity and thanks employees for their loyalty and effort FRISCO, Texas, Feb. 28, 2022 /PRNewswire/ -- Argon Medical Devices, Inc., a leading manufacturer of medical devices for interventional procedures, announces its 50th anniversary. This impressive milestone ...
2022-02-28 18:00
3934
Transcenta Announces First Patient Dosed in Phase IIa Study of Claudin18.2 Monoclonal Antibody TST001 Combined with Cisplatin and Gemcitabine for the First Line Treatment of Biliary Tract Cancer
SUZHOU, China, Feb. 28, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces the successful dosing...
2022-02-28 10:03
3665
First-ever Shingles Awareness Week highlights misconceptions about the risk of developing shingles among older adults, and the need for more education
* GSK has launched the inaugural Shingles Awareness Week to educate the general public about shingles in collaboration with the International Federation on Ageing * Over 90% of adults, above the age of 50, already carry the virus that causes shingles, and 1 in 3 adults will develop shingles i...
2022-02-28 10:00
2141
ALPS PHARMA LAUNCHES A NEW QUERCETIN DELIVERY COMPOSITION
HIDA, Japan, Feb. 28, 2022 /PRNewswire/ -- ALPS Pharmaceutical Ind. Co., Ltd. (President:Osamu Ushimaru), a global pharmaceutical company pioneering phytochemicals in medicine and food,today announced the launch of a water-soluble Quercetin delivery composition, Eubioflavonoid® derived from Sopho...
2022-02-28 09:19
2055
ALPS PHARMA LAUNCHES A NEW WATER-SOLUBLE ISOQUERCETIN COMPOSITION WITH HIGHER ABSORPTION RATE
HIDA, Japan, Feb. 28, 2022 /PRNewswire/ -- ALPS Pharmaceutical Ind. Co., Ltd. (President:Osamu Ushimaru), a global pharmaceutical company that pioneered the use of phytochemicals in medicine and food, announced the launch of a new Isoquercetin composition, Eubio®Isoquercetin,today. Eubio®Isoqu...
2022-02-28 09:16
2157
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Atopic Dermatitis
HANGZHOU, China, Feb. 28, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it had dosed the first patient with LNK01001 in its Phase II clinical trial on subjects with atopic dermatitis (A...
2022-02-28 08:00
4336
JW Therapeutics Announces NMPA Acceptance of the Supplemental New Drug Application for Carteyva® in Patients with Relapsed or Refractory Follicular Lymphoma
SHANGHAI, Feb. 27, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) ofChina accepted the sup...
2022-02-27 18:30
7084
First patient treated in cohort 2 SARTATE™ neuroblastoma therapy trial
SYDNEY, Feb. 25, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has successfully treated its first participant in cohort ...
2022-02-25 22:04
3913
Jean-Luc Herbeaux to become Hovione CEO
LISBON, Portugal, Feb. 25, 2022 /PRNewswire/ -- Hovione today announced that
the Board of Directors and the shareholders have approved the appointment of
Dr. Jean-Luc Herbeaux as Hovione's Chief Executive Officer, effective1st April
2022.
2022-02-25 22:00
3757
Daewoong Pharmaceutical Announces Successful Phase 3 Topline Results for New Antidiabetic Drug's Triple Combination Therapy
SEOUL, South Korea, Feb. 25, 2022 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) announced the topline results of the phase 3 clinical trial for a triple combination therapy of Enavogliflozin, a new antidiabetic drug with the mechanism of SGLT-2 inhibitor, with Metformin and Gemigliptin. Enav...
2022-02-25 22:00
4060
Terumo and Corazon Sign Collaboration and Co-Marketing Agreement
SOMERSET, N.J., Feb. 25, 2022 /PRNewswire/ -- Terumo Health Outcomes, a division of Terumo Medical Corporation, a leading global medical device manufacturer, has signed a collaboration and co-marketing agreement with Corazon, Inc., a leader in providing consulting, recruitment, interim managemen...
2022-02-25 22:00
4420
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 310 media titles]
2026-10-27 13:40
Hong Leong Bank Strengthens Cross-Border Payment Connectivity through Partnership with UnionPay International
[Picked up by 294 media titles]
2026-10-28 12:12
Agoda becomes first travel platform regionally to seamlessly connect with Meta's Muse
[Picked up by 294 media titles]
2026-10-28 09:00
OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW
[Picked up by 277 media titles]
2026-10-28 09:00
Pepperstone and Aston Martin Aramco extend and expand partnership with Fernando Alonso appointed Global Ambassador from 2027.
[Picked up by 276 media titles]
2026-10-29 13:01
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
52884
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
51703
